Strains for Day: A Trade Label Whose Genome Is Not Confirmed

• How much evidence. 3 works from 2015 to 2022, all listed in the table below along with the model.
• What was not demonstrated. No study has been published checking whether the strain described as daytime actually impairs alertness or performance during the day less than any other. The division into daytime and nighttime strains is not a clinically studied category.
• What you won’t find here. Dosage recommendations or strain indications. The choice is made by the attending physician, and cannabis flower is a raw material issued only by a doctor’s prescription.
• How to read this. The result of a study on rodents or in cell culture does not directly transfer to a patient taking flower, and the column with the model indicates what the work was actually about.

Does any study indicate daytime strains?

None. No clinical work has been created that compares the strain described as daytime with another in terms of alertness or performance during the day. The three available works concern the genetics and chemistry of the plant, not the patient, and all three undermine the very division from which this label arises. Below is what was measured in them.

The 2021 work in Nature Plants compared chemical designations with the genotype of the same plants. With over one hundred thousand checked polymorphic sites, the boundary between material described as sativa and material described as indica did not appear at all. The labels came from suppliers, the samples were not randomized, so this is a picture of the market, not an experiment with random assignment.

The other two positions approach the same from a different angle. Analysis of commercial samples from six US states found repeatable chemical groups, but the sales names only partially adhered to them. Older genotyping of over fourteen thousand sites yielded moderate, not zero, agreement, and this is how we describe it here.

No study has been published checking whether the strain described as daytime actually impairs alertness or performance during the day less than any other. The division into daytime and nighttime strains is not a clinically studied category, but a commercial description derived from the sativa and indica pair, and this pair does not genetically separate plants. The label is at most related to the terpene composition, and no one has measured the effect of this composition on human alertness.

Where did the sativa and indica pair come from?

From trade and horticulture, not from patient research. The pair described the plant’s morphology and geographical origin, and only later was a promise of stimulation or calming added to it. The genetics of this duo does not confirm: the declared origin explains the structure of strains only moderately, as shown by the genotyping from 2015 (PMID:26308334).

This same position yielded a result that shows how loose the label can be. Industrial hemp was found genetically closer to indica-type plants than to sativa-type plants. Material grown for fiber has nothing to do with the time of day, yet it lands on one side of the division by which the market describes the expected effect.

The boundaries of this work are mentioned along with its result. It genotyped 14,031 polymorphic sites in 43 samples of industrial hemp and in 81 samples of psychoactive cannabis, so on material collected conveniently, not randomly, and with a density lower than in newer analyses. The agreement called moderate is not any agreement, and this should not be taken away from it.

Newer data do not reverse anything here. When material with both labels was compared on a genome-wide scale, there was nothing to separate, and the difference between the plants lay elsewhere, in several volatile compounds.

What strain characteristics can be measured here?

Volatile composition and chemotype, meaning what is visible in the analysis of the sample. The label was associated in the 2021 work with the content of several terpenes, and their concentration is determined by genetic variants in clusters of genes coding for terpene synthases. This is where the measurable trace of the label ends.

The trace is narrow and does not lead to the patient. The content of compounds in the plant was measured, not alertness in humans, and there is no study standing between the two. Adding a promise of stimulation to the volatile profile would be a conclusion that no one has verified, though it sounds credible.

Individual terpenes are described separately, along with what is not known about them: terpinolene, limonene and myrcene. None of these pages assigns a time of day to the compound, as such measurement in humans does not exist.

Analysis of commercial samples from six US states showed that repeatable chemical groups really exist. The problem is not chemistry, but the assignment of names: some labels lean towards one chemotype more often than would be expected by chance, but never exclusively (PMID:35588111).

Does the strain name promise the composition of a specific batch?

No, it does not promise it bindingly. The authors of the analysis of commercial samples state directly that the adopted nomenclature can be detached from the chemistry of the material it is meant to describe. The name carries information about the grower and the batch, not a guarantee of consistent composition in the next delivery. The pharmacy register describes the position, not the plant.

Previous genotyping reached a consistent conclusion from the genomic side: strain names often do not designate a distinct genetic identity, so two batches under one label can be different plants. The authors do not claim that names are worthless; they claim that they do not have the power attributed to them.

For the patient in Poland, this has a practical effect. The pharmacy position is identified by the registered name along with the manufacturer, not by an adjective from the store description. We maintain a current list of these positions in the list of available strains, as the market composition changes faster than the content of the article.

The practical conclusion is modest and is meant to be so. The same name from two manufacturers can be two separate registered positions, with separately studied compositions, and the coincidence of names does not constitute evidence of material coincidence. What remains verifiable is what the manufacturer declared for a given series and what the analysis of that series showed, and only on this can anything be based.

What does the doctor decide, and what does the patient?

The choice of raw material is made by the attending physician. Cannabis flower is issued in Poland only by a doctor’s prescription in the Rpw category, so the daytime label is not a selection criterion available to the patient in the store. The patient brings observations: time of intake, tolerance, symptoms, and these return to the doctor as material for decision-making.

The doctor weighs things that no label contains: diagnosis, previous treatment, list of other preparations, and route of administration. The trade name enters this conversation at most as a shorthand that the patient uses to describe previous experience, and this is how it is read.

This page does not indicate any position or any manufacturer and does not suggest what to replace the doctor’s decision with. We describe only what follows from three works about the plant, and what does not follow from them. Cannabis flower is a pharmaceutical raw material issued by a doctor’s prescription in the Rpw category, and advertising of prescription medicinal products directed to the public is prohibited.

The division of roles can be confused when the store text presents the label as a hint. The commercial description does not have the status of information about a medicinal product; such a role is fulfilled by the product characteristics and leaflet, which the doctor and pharmacist refer to. The difference is not a formality, as it determines whose knowledge is responsible for the consequences.

How quickly does the flower start to work and how long does it last?

This depends on the route of administration, not on whether the strain is called daytime. The difference between inhaling vapor and swallowing can reach hours and is greater than any difference between cultivars described in available works. The following description therefore concerns the route of administration and should be read as such.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After swallowing, the raw material first passes through the intestine and liver, so the first sensations are waited for from half an hour to two, and the episode lasts six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks after thirty minutes that nothing is happening and adjusts the dose will receive both doses at once. The above ranges describe the route of administration, not this strain; pharmacokinetic studies for a single cultivar have not been published.

What adverse effects have been described in studies on daytime strains?

None. The three works on which this page stands studied plant material, not patients, so they did not collect reports of symptoms. Therefore, there is no separate compilation of adverse effects for strains described as daytime, as there is also no clinical study that has isolated such a group.

Reports of adverse effects are collected for a medicinal product with a batch number, not for a strain name, so the following concerns cannabis flower as a group of raw materials. The most commonly reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and transient worsening of short-term memory are less frequently reported, as well as anxiety increasing with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for cannabis flower in Poland do not separate them by individual products.

It is also not possible to provide frequency separately for material described as daytime, as reports do not have such a column. The trade label does not enter the documentation of the registered position, so even if someone collected a complete set of data, they would have nothing to separate the daytime group from the rest of the flower.

What remains from the daytime label when its promise is removed?

What remains is a commercial description and a narrow chemical trace. The label can be a shorthand for the seller, useful in conversation, but it does not describe either the genome of the plant or the reaction of the human. Everything that can be said about the position from documents stands in its register, not in the adjective attached to the name.

The other half of the same label has a separate text about night strains, where there is also a meta-analysis concerning sleep. On the daytime side, there is no equivalent of such work, and this is the most important difference between the two halves of the division.

The availability of pharmacy positions changes from month to month, as it depends on approvals and wholesale supplies, and besides, there is a store section with flower without a prescription. The description that can be verified lists the manufacturer, registered name, and tested composition, not the time of day.

So instead of an adjective, what remains is documentation: batch number, manufacturer, declared content of active substances, and the result of the profile analysis, if the manufacturer has made such a result available. This is material poorer than the promise of the time of day, but verifiable, and the distance between one and the other is precisely the subject of this page.

Frequently Asked Questions

Is a sativa strain a daytime strain?

No in the sense that could be verified. Samples labeled as sativa and samples labeled as indica did not separate in the analysis of the entire genome, so the label itself does not designate a group of plants with different effects.

Does the daytime label result from the terpene profile?

Partially. The label was associated with the content of several terpenes, for which genetic variants in clusters of genes coding for terpene synthases are responsible. However, no one has checked whether this difference translates to alertness in humans.

Does the strain name guarantee the same composition in every delivery?

No. In commercial samples, repeatable chemotypes can be distinguished, but sales names do not consistently correspond to them, and the dependence can be more frequent than random, but never exclusive.

Who decides on the choice of strain when treating with cannabis?

The attending physician, as cannabis flower is issued by a doctor’s prescription in the Rpw category. The patient reports observations and symptoms, while the choice of pharmacy position remains a medical decision.

How long does the effect of flower last after vaporization, and how long after swallowing?

After vaporization, the first sensations appear after a few minutes, and the whole effect lasts for two to four hours. After swallowing, the initial wait is from half an hour to two, and the episode lasts six, sometimes eight hours.

Have adverse effects been described in studies on daytime strains?

No, because such studies do not exist. Reports are collected for a medicinal product with a batch number, and among the symptoms, dry mouth, red eyes, and increased heart rate are the most frequently repeated.

The material is for informational purposes and does not replace medical advice or the content of the medicinal product leaflet.

Editorial text: ubucha.